Company Estrella Immunopharma, Inc.

Equities

ESLA

US2975841048

Biotechnology & Medical Research

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sector Bio Therapeutic Drugs

End-of-day quote Nasdaq Other stock markets 06:00:00 2024-07-08 pm EDT			5-day change	1st Jan Change
1.15 ^USD	-7.22%		+0.48%	+3.65%

Jul. 01	Estrella Immunopharma, Inc.(NasdaqCM:ESLA) added to Russell Microcap Growth Index	CI
Jul. 01	Estrella Immunopharma, Inc.(NasdaqCM:ESLA) added to Russell 3000E Index	CI

Estrella Immunopharma, Inc. is a preclinical-stage biopharmaceutical company. The Company is developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Its lead product candidate, EB103, utilizes Eureka's ARTEMIS technology to target CD19, a protein expressed on the surface of almost all B-cell leukemias and lymphomas. The Company is also developing EB104, which also utilizes Eureka's ARTEMIS technology to target not only CD19, but also CD22, a protein that, like CD19, is expressed on the surface of most B-cell malignancies. The Company is also collaborating with Imugene Limited and its product candidate, CF33-CD19t an oncolytic virus (CF33-CD19t), to research the use of EB103 in conjunction with CF33-CD19t to treat solid tumors.

Managers	Title	Age	Since
Cheng Liu CEO	Chief Executive Officer	57	-
Jiandong Xu DFI	Director of Finance/CFO	54	-
Vicky Yang COO	Chief Operating Officer	52	-

Members of the board	Title	Age	Since
Cheng Liu CEO	Chief Executive Officer	57	-
Pei Xu BRD	Director/Board Member	42	-
Marsha Roberts BRD	Director/Board Member	55	-
Fan Wu BRD	Director/Board Member	51	-
Janelle Wu BRD	Director/Board Member	-	-

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	36,376,293	10,536,637 ( 28.97 %)	0	28.97 %

Name	Equities	%	Valuation
Eureka Therapeutics, Inc. 69.49 %	25,277,831	69.49 %	27 M $
TradeuUP Acquisition Sponsor LLC 3.056 %	1,111,760	3.056 %	1 M $
Cheng Liu 0.8177 %	297,437	0.8177 %	312 309 $
Jiandong Xu 0.7268 %	264,388	0.7268 %	277 607 $
Jian Wei Li 0.3903 %	141,970	0.3903 %	149 069 $
UP FINTECH HOLDING LIMITED 0.3738 %	135,970	0.3738 %	142 769 $
Geode Capital Management LLC 0.1600 %	58,214	0.1600 %	61 125 $
ATW SPAC Management LLC 0.1100 %	40,000	0.1100 %	42 000 $
Hunting Hill Global Capital LLC 0.0587 %	21,358	0.0587 %	22 426 $
James Long 0.0275 %	10,000	0.0275 %	10 500 $

Name	Equities	%	Valuation
Highbridge Capital Management LLC -	413,517	-	23 984 $
Boothbay Fund Management LLC -	189,899	-	11 014 $
D.E. Shaw & Co., Inc. -	87,500	-	5 075 $
Walleye Capital LLC -	66,112	-	3 834 $
SkyView Investment Advisors LLC -	62,500	-	3 625 $
Yakira Capital Management, Inc. -	46,485	-	2 696 $
Whitebox Advisors LLC -	45,476	-	2 638 $
Walleye Trading LLC -	37,188	-	2 157 $
Cowen & Co. LLC -	28,597	-	1 659 $
Clear Street LLC -	28,591	-	1 658 $

Estrella Immunopharma, Inc.

5858 Horton Street Suite 370

94608, Emeryville

address Estrella Immunopharma, Inc.(ESLA)

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
ESTRELLA IMMUNOPHARMA, INC.	+3.65%	49.47M
VERTEX PHARMACEUTICALS INCORPORATED	+21.25%	127B
REGENERON PHARMACEUTICALS, INC.	+25.20%	117B
ARGENX SE	+25.56%	27.77B
BIONTECH SE	-20.37%	20.44B
GENMAB A/S	-14.36%	16.62B
BEIGENE, LTD.	-13.76%	15.92B
WUXI APPTEC CO., LTD.	-46.67%	14.94B
NEUROCRINE BIOSCIENCES, INC.	+12.27%	14.74B
SAREPTA THERAPEUTICS, INC.	+56.22%	14.38B

Bio Therapeutic Drugs